Creating Hope Reauthorization Act of 2024

The Creating Hope Reauthorization Act of 2024 extends the expiration date of the priority review voucher program for rare pediatric disease treatments from September 30, 2024, to September 30, 2030. This program, established under the Federal Food, Drug, and Cosmetic Act, allows the FDA to issue priority review vouchers to pharmaceutical companies that develop treatments for rare pediatric diseases. These vouchers enable companies to expedite FDA review of other drug applications, creating a financial incentive to invest in rare disease research. The extension ensures continued support for developing treatments for rare pediatric conditions through 2030.